Divalproex Sodium Tablet, Extended Release
Product Images NDC 68180-261

10 FDA label images from Lupin Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68180-261). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1 (1638e85a 579b 4286 8f77 49f9e6c88488 01)

Image 1 (1638e85a 579b 4286 8f77 49f9e6c88488 01)
Chemical structure of the active ingredient divalproex sodium, depicting the molecular components including carboxyl groups, alkyl chains, and sodium ion association.*
FDA Label Image

Image 2 (1638e85a 579b 4286 8f77 49f9e6c88488 02)

Image 2 (1638e85a 579b 4286 8f77 49f9e6c88488 02)
A cumulative distribution plot comparing percent reduction in CPS rate between Divalproex Sodium Delayed-Release and placebo. The vertical axis shows percent reduction in CPS rate ranging from -100% (worsening) to 100% (improvement), and the horizontal axis shows percent of patients from 0 to 100%. Two curves represent patient response distribution for each treatment group.*
FDA Label Image

Image 3 (1638e85a 579b 4286 8f77 49f9e6c88488 03)

Image 3 (1638e85a 579b 4286 8f77 49f9e6c88488 03)
A cumulative distribution plot depicting the percentage reduction in CPS Rate against the percentage of patients treated with high and low doses of Divalproex Sodium Delayed Release. The vertical axis represents improvement or worsening, while two lines compare responses for high dose (solid line) and low dose (dashed line) over the patient population.*
FDA Label Image

Image 4 (1638e85a 579b 4286 8f77 49f9e6c88488 04)

Image 4 (1638e85a 579b 4286 8f77 49f9e6c88488 04)
A bar graph comparing the effect of Placebo versus Divalproex Sodium Extended-Release Tablets, showing a higher measured value for the Divalproex Sodium group. The graph includes an asterisk indicating statistical significance with a p-value of 0.006.*
FDA Label Image

Image (9f0c730e 9756 4a9a 9277 B4ef5ca07604 201 1)

Image (9f0c730e 9756 4a9a 9277 B4ef5ca07604 201 1)
The image shows a bottle label for Divalproex sodium extended-release tablets by Lupin Pharmaceuticals, Inc. It indicates the oral tablet dosage form, with available strengths of 250 mg and 500 mg. The label design includes a distinct black and white pattern on the bottle.*
FDA Label Image

Image (1fc9a662 2c99 4c65 B31c Ebee40f357aa 232 1)

FDA Label Image

250 mg-100 Pack (1638e85a 579b 4286 8f77 49f9e6c88488 05)

250 mg-100 Pack (1638e85a 579b 4286 8f77 49f9e6c88488 05)
Label for Divalproex Sodium Extended-Release Tablets, USP, 250 mg, once-daily dosing oral tablets. The label indicates a bottle containing 100 tablets, manufactured by Lupin Pharmaceuticals, Inc. The label includes storage instructions, dosage guidance, and a QR code for the medication guide.*
FDA Label Image

Image 6 (1638e85a 579b 4286 8f77 49f9e6c88488 06)

Image 6 (1638e85a 579b 4286 8f77 49f9e6c88488 06)
Label for Divalproex Sodium Extended-Release Tablets, USP 250 mg. Tablets are oral, extended-release dosage form with valproic acid activity. The label indicates once-daily dosing and a quantity of 500 tablets. Manufactured by Lupin Pharmaceuticals, Inc. with the labeler Lupin Limited in India. Includes storage instructions and directions to dispense with a medication guide.*
FDA Label Image

500 mg- 100 Pack (1638e85a 579b 4286 8f77 49f9e6c88488 07)

500 mg- 100 Pack (1638e85a 579b 4286 8f77 49f9e6c88488 07)
Label for Divalproex Sodium Extended-Release Tablets, USP 500 mg, oral extended-release tablets. The label includes directions for once-daily dosing, pharmacy instructions to dispense the medication guide, and states the package contains 100 tablets. Manufactured by Lupin Pharmaceuticals, Inc. with storage and handling instructions provided.*
FDA Label Image

500 mg (500 pack)

500 mg (500 pack)
Label for Divalproex Sodium Extended-Release Tablets, USP 500 mg by Lupin Pharmaceuticals, Inc. The label indicates 500 mg strength, extended-release oral tablets with 500 tablets per package. It includes storage instructions, a barcode, and manufacturer details for Lupin Pharmaceuticals in the USA and Lupin Limited in India. The label also provides dosing information and directs users to a medication guide via a QR code or website.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.